Eosinophilic esophagitis (EoE) - Epidemiology Forecast to 2027

October 2018 | 57 pages | ID: E93F371CAB3EN
DelveInsight

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight’s ‘Eosinophilic esophagitis (EoE) - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Eosinophilic esophagitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

GEOGRAPHY COVERED

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Eosinophilic esophagitis (EoE)

The Eosinophilic esophagitis (EoE) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Eosinophilic esophagitis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Eosinophilic esophagitis (EoE) Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, Sex-Specific Prevalent cases, Age-Specific Prevalent cases and Prevalent cases by Clinical Manifestation (Dysphagia, abdominal pain, chest pain, allergic disease)) scenario of Eosinophilic esophagitis (EoE) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total prevalent population of Eosinophilic esophagitis (EoE) was found to be 433,358, in the year 2016 in 7MM.

REPORT SCOPE

• The report covers detailed overview of Eosinophilic esophagitis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Eosinophilic esophagitis in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by type i.e., Sex-Specific, Age-Specific Prevalence and Prevalence by Clinical Manifestation) in 7MM

KEY STRENGTHS

• 10 Year Forecast of Eosinophilic esophagitis (EoE)
• 7MM Coverage
• Total Prevalent Cases of EoE
• Prevalent Cases according to segmentation: Sex-Specific, Age-Specific and by Clinical Manifestation.

KEY ASSESSMENTS

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. DISEASE BACKGROUND AND OVERVIEW: EOSINOPHILIC ESOPHAGITIS (EOE)

2.1. Introduction
2.2. Pathophysiology
2.3. Causes
2.4. Risk factors
2.5. Signs and Symptoms
2.6. Clinical Manifestations
2.7. Diagnosis
2.8. Monitoring Tools

3. EPIDEMIOLOGY AND PATIENT POPULATION

3.1. Key Findings
3.2. Population and Forecast Parameters

4. 7MM TOTAL PREVALENT PATIENT POPULATION OF EOSINOPHILIC ESOPHAGITIS

4.1. Country Wise-Epidemiology of Eosinophilic esophagitis (EoE)
  4.1.1. United States
    4.1.1.1. Total Prevalent Patient Population of Eosinophilic Esophagitis in the United States
    4.1.1.2. Sex-Specific Prevalence of Eosinophilic Esophagitis in the United States
    4.1.1.3. Age-Specific Prevalence of Eosinophilic Esophagitis in the United States
    4.1.1.4. Prevalence by Clinical Manifestation- Eosinophilic Esophagitis
  4.1.2. EU5 Countries
  4.1.3. Germany
    4.1.3.1. Total Prevalent Patient Population of Eosinophilic Esophagitis in Germany
    4.1.3.2. Sex-Specific Prevalence of Eosinophilic Esophagitis in Germany
    4.1.3.3. Age-Specific Prevalence of Eosinophilic Esophagitis in Germany
    4.1.3.4. Prevalence by Clinical Manifestation- Eosinophilic Esophagitis
  4.1.4. France
    4.1.4.1. Total Prevalent Patient Population of Eosinophilic Esophagitis in France
    4.1.4.2. Sex-Specific Prevalence of Eosinophilic Esophagitis in France
    4.1.4.3. Age-Specific Prevalence of Eosinophilic Esophagitis in France
    4.1.4.4. Prevalence by Clinical Manifestation- Eosinophilic Esophagitis
  4.1.5. Italy
    4.1.5.1. Total Prevalent Patient Population of Eosinophilic Esophagitis in Italy
    4.1.5.2. Sex-Specific Prevalence of Eosinophilic Esophagitis in Italy
    4.1.5.3. Age-Specific Prevalence of Eosinophilic Esophagitis in Italy
    4.1.5.4. Prevalence by Clinical Manifestation- Eosinophilic Esophagitis
  4.1.6. Spain
    4.1.6.1. Total Prevalent Patient Population of Eosinophilic Esophagitis in Spain
    4.1.6.2. Sex-Specific Prevalence of Eosinophilic Esophagitis in Spain
    4.1.6.3. Age-Specific Prevalence of Eosinophilic Esophagitis in Spain
    4.1.6.4. Prevalence by Clinical Manifestation- Eosinophilic Esophagitis
  4.1.7. United Kingdom
    4.1.7.1. Total Prevalent Patient Population of Eosinophilic Esophagitis in the United Kingdom
    4.1.7.2. Sex-Specific Prevalence of Eosinophilic Esophagitis in the United Kingdom
    4.1.7.3. Age-Specific Prevalence of Eosinophilic Esophagitis in the United Kingdom
    4.1.7.4. Prevalence by Clinical Manifestation- Eosinophilic Esophagitis
  4.1.8. Japan
    4.1.8.1. Total Prevalent Patient Population of Eosinophilic Esophagitis in Japan
    4.1.8.2. Sex-Specific Prevalence of Eosinophilic Esophagitis in Japan
    4.1.8.3. Age-Specific Prevalence of Eosinophilic Esophagitis in Japan
    4.1.8.4. Prevalence by Clinical Manifestation- Eosinophilic Esophagitis

5. APPENDIX

5.1. Report Methodology

6. DELVEINSIGHT CAPABILITIES

7. DISCLAIMER

8. ABOUT DELVEINSIGHT

List Of Tables

LIST OF TABLES

Table 1: Clinical manifestations of EoE
Table 2: Endoscopic features of EoE
Table 3: Total Prevalent Patient Population of Eosinophilic Esophagitis in the 7MM (2016-2027)
Table 4: Total Prevalent Population of Eosinophilic Esophagitis in the US (2016-2027)
Table 5: Sex-Specific Prevalence of Eosinophilic Esophagitis in the US (2016-2027)
Table 6: Age-Specific Prevalent Population of Eosinophilic Esophagitis in the US (2016-2027)
Table 7: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Table 8: Total Prevalent Population of Eosinophilic Esophagitis in Germany (2016-2027)
Table 9: Sex-Specific Prevalence of Eosinophilic Esophagitis in Germany (2016-2027)
Table 10: Age-Specific Prevalent Population of Eosinophilic Esophagitis in Germany (2016-2027)
Table 11: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Table 12: Total Prevalent Population of Eosinophilic Esophagitis in France (2016-2027)
Table 13: Sex-Specific Prevalence of Eosinophilic Esophagitis in France (2016-2027)
Table 14: Age Specific Prevalent Population of Eosinophilic Esophagitis in France (2016-2027)
Table 15: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Table 16: Total Prevalent Population of Eosinophilic Esophagitis in Italy (2016-2027)
Table 17: Sex-Specific Prevalence of Eosinophilic Esophagitis in Italy (2016-2027)
Table 18: Age-Specific Prevalent Population of Eosinophilic Esophagitis in Italy (2016-2027)
Table 19: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Table 20: Total Prevalent Population of Eosinophilic Esophagitis in Spain (2016-2027)
Table 21: Sex-Specific Prevalence of Eosinophilic Esophagitis in Spain (2016-2027)
Table 22: Age-Specific Prevalent Population of Eosinophilic Esophagitis in Spain (2016-2027)
Table 23: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Table 24: Total Prevalent Population of Eosinophilic Esophagitis in the UK (2016-2027)
Table 25: Sex-Specific Prevalence of Eosinophilic Esophagitis in the UK (2016-2027)
Table 26: Age-Specific Prevalent Population of Eosinophilic Esophagitis in the UK (2016-2027)
Table 27: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Table 28: Total Prevalent Population of Eosinophilic Esophagitis in Japan (2016-2027)
Table 29: Sex-Specific Prevalence of Eosinophilic Esophagitis in Japan (2016-2027)
Table 30: Age-Specific Prevalent Population of Eosinophilic Esophagitis in Japan (2016-2027)
Table 31: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)

List Of Figures

LIST OF FIGURES

Figure 1: Pathophysiological mechanism involved in Eosinophilic infiltration of esophageal mucosa
Figure 2: Signs and Symptoms of Eosinophilic esophagitis (EoE)
Figure 3: Total Prevalent Patient Population of Eosinophilic Esophagitis in the 7MM (2016-2027)
Figure 4: Total Prevalent Population of Eosinophilic Esophagitis in the US (2016-2027)
Figure 5: Sex-Specific Prevalence of Eosinophilic Esophagitis in the US (2016-2027)
Figure 6: Age-Specific Prevalent Population of Eosinophilic Esophagitis in the US (2016-2027)
Figure 7: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Figure 8: Total Prevalent Population of Eosinophilic Esophagitis in Germany (2016-2027)
Figure 9: Sex-Specific Prevalence of Eosinophilic Esophagitis in Germany (2016-2027)
Figure 10: Age-Specific Prevalent Population of Eosinophilic Esophagitis in Germany (2016-2027)
Figure 11: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Figure 12: Total Prevalent Population of Eosinophilic Esophagitis in France (2016-2027)
Figure 13: Sex-Specific Prevalence of Eosinophilic Esophagitis in France (2016-2027)
Figure 14: Age Specific Prevalent Population of Eosinophilic Esophagitis in France (2016-2027)
Figure 15: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Figure 16: Total Prevalent Population of Eosinophilic Esophagitis in Italy (2016-2027)
Figure 17: Sex-Specific Prevalence of Eosinophilic Esophagitis in Italy (2016-2027)
Figure 18: Age-Specific Prevalent Population of Eosinophilic Esophagitis in Italy (2016-2027)
Figure 19: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Figure 20: Total Prevalent Population of Eosinophilic Esophagitis in Spain (2016-2027)
Figure 21: Sex-Specific Prevalence of Eosinophilic Esophagitis in Spain (2016-2027)
Figure 22: Age Specific Prevalent Population of Eosinophilic Esophagitis in Spain (2016-2027)
Figure 23: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Figure 24: Total Prevalent Population of Eosinophilic Esophagitis in the UK (2016-2027)
Figure 25: Sex-Specific Prevalence of Eosinophilic Esophagitis in the UK (2016-2027)
Figure 26: Age-Specific Prevalent Population of Eosinophilic Esophagitis in the UK (2016-2027)
Figure 27: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)
Figure 28: Total Prevalent Population of Eosinophilic Esophagitis in Japan (2016-2027)
Figure 29: Sex-Specific Prevalence of Eosinophilic Esophagitis in Japan (2016-2027)
Figure 30: Age-Specific Prevalent Population of Eosinophilic Esophagitis in Japan (2016-2027)
Figure 31: Prevalence of Eosinophilic Esophagitis by clinical manifestation (2016-2027)